Merck KGaA, Darmstadt, Germany, Places Bonds Amounting to €1.0 billion
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today successfully issued bonds amounting to € 1.0 billion. The revenue from the bond issue will be used for general corporate purposes, including refinancing of short-term financial liabilities.
The issuance comprises two fixed-interest tranches: a bond with a term of four years amounting to € 500 million paying a coupon of 1.875%, as well as a bond amounting to € 500 million with a term of eight years paying a coupon of 2.375%.
“The high investor demand for our bonds, also in such volatile times, shows the strong believe in the financial discipline of our company,” said Marcus Kuhnert, Member of the Executive Board and Chief Financial Officer of Merck KGaA, Darmstadt, Germany. Achieving a well-diversified distribution among a wide range of institutional investors such as fund managers, insurance companies, pension funds, and banks, the bonds were heavily oversubscribed.
The active bookrunners commissioned for the transaction were JP Morgan Chase, Bank of America Merrill Lynch, Deutsche Bank, Mizuho Bank, and UniCredit Bank.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity.